PMID- 33631216
OWN - NLM
STAT- MEDLINE
DCOM- 20220301
LR  - 20220301
IS  - 1097-6787 (Electronic)
IS  - 0190-9622 (Linking)
VI  - 85
IP  - 3
DP  - 2021 Sep
TI  - Comparative safety and benefit-risk profile of biologics and oral treatment for 
      moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial 
      data.
PG  - 572-581
LID - S0190-9622(21)00422-9 [pii]
LID - 10.1016/j.jaad.2021.02.057 [doi]
AB  - BACKGROUND: The comparative safety and benefit-risk profiles of 
      moderate-to-severe psoriasis treatment have not been well studied. OBJECTIVE: To 
      compare the short-term (12-16 weeks) and long-term (48-56 weeks) safety and 
      benefit-risk profiles of moderate-to-severe psoriasis treatments. METHODS: A 
      systematic literature review of phase II-IV randomized controlled trials of 
      moderate-to-severe psoriasis treatments was conducted (cutoff: July 1, 2020). Any 
      adverse events (AEs), any serious AEs, and AEs leading to treatment 
      discontinuation were compared using Bayesian network meta-analyses (NMAs). 
      RESULTS: Fifty-two and 7, respectively, randomized controlled trials were 
      included in the short- and long-term NMAs, respectively. In the short-term NMA, 
      the rates of any AEs were the lowest for tildrakizumab (posterior median: 46.0%), 
      certolizumab (46.2%), and etanercept (49.1%). The rates of any serious AE were 
      the lowest for certolizumab (0.8%), risankizumab (1.2%), and etanercept (1.6%). 
      The rates of AEs leading to treatment discontinuation were the lowest for 
      risankizumab (0.5%), tildrakizumab (1.0%), and guselkumab (1.5%). In the 
      long-term NMA, risankizumab had the lowest rates of all 3 outcomes (67.5%, 4.4%, 
      and 1.0%, respectively) and the most favorable benefit-risk profile. LIMITATIONS: 
      The results may not be generalizable to real-world populations. CONCLUSIONS: 
      Anti-interleukin 23 agents were associated with low rates of safety events. 
      Risankizumab had the most favorable benefit-risk profile in the long term.
CI  - Copyright (c) 2021 American Academy of Dermatology, Inc. Published by Elsevier Inc. 
      All rights reserved.
FAU - Shear, Neil H
AU  - Shear NH
AD  - Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.
FAU - Betts, Keith A
AU  - Betts KA
AD  - Analysis Group, Inc, Los Angeles, California.
FAU - Soliman, Ahmed M
AU  - Soliman AM
AD  - AbbVie, North Chicago, Illinois.
FAU - Joshi, Avani
AU  - Joshi A
AD  - AbbVie, North Chicago, Illinois.
FAU - Wang, Yan
AU  - Wang Y
AD  - Analysis Group, Inc, Los Angeles, California.
FAU - Zhao, Jing
AU  - Zhao J
AD  - Analysis Group, Inc, Denver, Colorado.
FAU - Gisondi, Paolo
AU  - Gisondi P
AD  - Department of Medicine, University of Verona, Verona, Italy.
FAU - Sinvhal, Ranjeeta
AU  - Sinvhal R
AD  - AbbVie, North Chicago, Illinois.
FAU - Armstrong, April W
AU  - Armstrong AW
AD  - Keck School of Medicine, University of Southern California, Los Angeles, 
      California. Electronic address: aprilarmstrong@post.harvard.edu.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210222
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
RN  - 0 (Biological Products)
RN  - OP401G7OJC (Etanercept)
RN  - UMD07X179E (Certolizumab Pegol)
SB  - IM
CIN - J Am Acad Dermatol. 2021 Nov;85(5):e305-e306. PMID: 34311042
MH  - Bayes Theorem
MH  - Biological Products/adverse effects
MH  - Certolizumab Pegol
MH  - Etanercept/adverse effects
MH  - Humans
MH  - Network Meta-Analysis
MH  - *Psoriasis/diagnosis/drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - network meta-analysis
OT  - outcomes
OT  - psoriasis
OT  - safety
OT  - treatment
COIS- Conflicts of interest Dr Shear is a paid consultant for AbbVie, Amgen, Lilly, 
      Leo, Bausch Health, Sun Pharma, Janssen, Galderma, Otsuka, UCB, Celgene, Sanofi 
      Genzyme, Novartis, and Pfizer. Drs Joshi, Soliman, and Sinvhal are employees of 
      AbbVie and may own AbbVie stock or stock options. Drs Betts, Wang, and Zhao are 
      employees of Analysis Group, Inc, which received payment from AbbVie Inc for 
      participation in this research. Dr Gisondi has served as a speaker or an advisory 
      board member for AbbVie, Almirall, Amgen, BMS, Celgene, Eli-Lilly, Janssen, 
      Leo-pharma, Merck, MSD, Novartis, Pfizer, Sanofi, Sandoz, and UCB Pharma. Dr 
      Armstrong has served as a research investigator or consultant to Leo, AbbVie, 
      UCB, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant, BMS, Sanofi, 
      Regeneron, Dermira, and Modmed.
EDAT- 2021/02/26 06:00
MHDA- 2022/03/03 06:00
CRDT- 2021/02/25 20:10
PHST- 2020/11/10 00:00 [received]
PHST- 2021/01/28 00:00 [revised]
PHST- 2021/02/04 00:00 [accepted]
PHST- 2021/02/26 06:00 [pubmed]
PHST- 2022/03/03 06:00 [medline]
PHST- 2021/02/25 20:10 [entrez]
AID - S0190-9622(21)00422-9 [pii]
AID - 10.1016/j.jaad.2021.02.057 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 2021 Sep;85(3):572-581. doi: 10.1016/j.jaad.2021.02.057. Epub 
      2021 Feb 22.